A peptide agonist of GLP-2R
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Apraglutide (acetate)

Item No. 45070

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-histidylglycyl-L-α-aspartylglycyl-L-seryl-L-phenyla lanyl-L-seryl-L-α-aspartyl-L-α-glutamyl-L-norleucyl-D-phenylalanyl-L-threonyl-L-isoleucyl-L-leucyl-L-α-aspartyl-L-leucyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-aspara ginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-L-α-asparagine, monoacetate
Synonyms
  • FE 203799
  • [Gly2, Nle10, D-Phe11, Leu16] hGLP-2 (1-33)-NH2)
Molecular Formula
C172H263N43O52 • XC2H4O2
Formula Weight
3765.2
Purity
≥98%
Formulation (Request formulation change)
A solid
Peptide Sequence
HGDGSFSDE-Nle-fTILDLLAARDFINWLIQTKITD-NH2
Solubility(Learn about Variance in Solubility)
DMSO: Slightly soluble: 0.1-1 mg/ml
SMILES
O=C(O)C[C@@H](C(N)=O)NC([C@H]([C@H](O)C)NC([C@H]([C@@H](C)CC)NC([C@H](CCCCN)NC([C@H]([C@H](O)C)NC([C@H](CCC(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CC(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC3=CC=CC=C3)NC([C@H](CC(O)=O)NC([C@H](CCCNC(N)=N)NC([C@H](C)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC([C@H]([C@@H](C)CC)NC([C@H]([C@H](O)C)NC([C@@H](CC4=CC=CC=C4)NC([C@H](CCCC)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H](CC5=CC=CC=C5)NC([C@H](CO)NC(CNC([C@H](CC(O)=O)NC(CNC([C@H](CC6=CNC=N6)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O
InChi Code
InChI=1S/C172H263N43O52.C2H4O2/c1-23-28-50-103(191-148(244)107(55-57-128(225)226)192-157(253)119(72-131(231)232)205-164(260)123(80-217)208-154(250)113(64-95-43-32-29-33-44-95)201-163(259)122(79-216)189-127(224)78-184-145(241)118(71-130(229)230)188-126(223)77-183-144(240)101(174)68-99-76-180-81-185-99)146(242)199-115(66-97-47-36-31-37-48-97)162(258)214-140(94(22)220)171(267)212-136(88(16)26-4)167(263)206-111(62-84(10)11)153(249)204-121(74-133(235)236)158(254)197-110(61-83(8)9)152(248)196-109(60-82(6)7)151(247)187-90(18)142(238)186-91(19)143(239)190-105(53-42-59-181-172(178)179)147(243)203-120(73-132(233)234)159(255)200-114(65-96-45-34-30-35-46-96)161(257)211-135(87(15)25-3)166(262)207-117(69-125(176)222)156(252)202-116(67-98-75-182-102-51-39-38-49-100(98)102)155(251)198-112(63-85(12)13)160(256)210-134(86(14)24-2)165(261)194-106(54-56-124(175)221)150(246)213-138(92(20)218)169(265)193-104(52-40-41-58-173)149(245)209-137(89(17)27-5)168(264)215-139(93(21)219)170(266)195-108(141(177)237)70-129(227)228;1-2(3)4/h29-39,43-49,51,75-76,81-94,101,103-123,134-140,182,216-220H,23-28,40-42,50,52-74,77-80,173-174H2,1-22H3,(H2,175,221)(H2,176,222)(H2,177,237)(H,180,185)(H,183,240)(H,184,241)(H,186,238)(H,187,247)(H,188,223)(H,189,224)(H,190,239)(H,191,244)(H,192,253)(H,193,265)(H,194,261)(H,195,266)(H,196,248)(H,197,254)(H,198,251)(H,199,242)(H,200,255)(H,201,259)(H,202,252)(H,203,243)(H,204,249)(H,205,260)(H,206,263)(H,207,262)(H,208,250)(H,209,245)(H,210,256)(H,211,257)(H,212,267)(H,213,246)(H,214,258)(H,215,264)(H,225,226)(H,227,228)(H,229,230)(H,231,232)(H,233,234)(H,235,236)(H4,178,179,181);1H3,(H,3,4)/t86-,87-,88-,89-,90-,91-,92+,93+,94+,101-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115+,116-,117-,118-,119-,120-,121-,122-,123-,134-,135-,136-,137-,138-,139-,140-;/m0./s1
InChi Key
CBUQUABRIXULIA-NCNHWARASA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $89

    Add

    5 mg

    $245

    Add

    10 mg

    $401

    Add
    Product Description

    Apraglutide is a peptide agonist of glucagon-like peptide 2 receptor (GLP-2R).1 It activates GLP-2R in a reporter assay using HEK293 cells expressing the human or rat receptor (EC50s = 0.03 and 0.07 nM, respectively). Apraglutide is selective for GLP-2R over GLP-1R (EC50 = >1,000 nM) and a panel of 73 receptors, five ion channels, and three transporters at 1 µM. Subcutaneous administration of apraglutide (5 mg/kg) increases intestinal length, small intestinal weight, villus height, and crypt depth and reduces fecal fat levels in a neonatal pig model of short bowel syndrome induced by intestinal and ileal resection.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hargrove, D.M., Alagarsamy, S., Croston, G., et al. Pharmacological characterization of apraglutide, a novel long-acting peptidic glucagon-like peptide-2 agonist, for the treatment of short bowel syndrome. J. Pharmacol. Exp. Ther. 373(2), 193-203 (2020).

    2. Slim, G.M., Lansing, M., Wizzard, P., et al. Novel long-acting GLP-2 analogue, FE 203799 (apraglutide), enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum. JPEN J. Parenter. Enteral Nutr. 43(7), 891-898 (2019).